Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Barry Ticho Sells 1,051 Shares

by · The Cerbat Gem

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) insider Barry Ticho sold 1,051 shares of Stoke Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $26.16, for a total transaction of $27,494.16. Following the sale, the insider directly owned 19,059 shares of the company’s stock, valued at $498,583.44. The trade was a 5.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

  • On Tuesday, September 1st, Barry Ticho sold 5,545 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.67, for a total transaction of $170,065.15.
  • On Tuesday, August 18th, Barry Ticho sold 4,767 shares of Stoke Therapeutics stock. The shares were sold at an average price of $32.03, for a total transaction of $152,687.01.
  • On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04.

Stoke Therapeutics Trading Down 1.5%

Shares of NASDAQ:STOK traded down $0.39 during trading on Friday, reaching $25.62. 581,420 shares of the stock were exchanged, compared to its average volume of 783,759. Stoke Therapeutics, Inc. has a 12 month low of $20.32 and a 12 month high of $40.22. The firm has a market cap of $1.65 billion, a PE ratio of -7.67 and a beta of 1.26. The stock has a 50-day moving average price of $29.99 and a 200-day moving average price of $31.21.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The firm had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. On average, sell-side analysts expect that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on STOK. Wedbush upped their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Canaccord Genuity Group dropped their target price on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday, August 7th. The Goldman Sachs Group reissued a “buy” rating on shares of Stoke Therapeutics in a research report on Thursday, September 10th. Finally, Chardan Capital restated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.25.

View Our Latest Research Report on STOK

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in STOK. BlackRock Inc. acquired a new stake in Stoke Therapeutics during the second quarter worth approximately $192,307,000. Redmile Group LLC raised its holdings in Stoke Therapeutics by 3.2% in the 1st quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock valued at $135,584,000 after acquiring an additional 130,050 shares in the last quarter. Wellington Management Group LLP raised its holdings in Stoke Therapeutics by 13.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,519,301 shares of the company’s stock valued at $115,152,000 after acquiring an additional 423,601 shares in the last quarter. BVF Inc. IL raised its holdings in Stoke Therapeutics by 36.7% in the 4th quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock valued at $71,912,000 after acquiring an additional 608,578 shares in the last quarter. Finally, Jupiter Topco LLC bought a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at $59,358,000.

Stoke Therapeutics Company Profile

(Get Free Report)

Stoke Therapeutics, Inc is a biotechnology company developing genetic medicines for severe diseases caused by inadequate protein expression. The company’s approach, known as TANGO (Targeted Augmentation of Nuclear Gene Output), uses antisense oligonucleotides to selectively modulate pre-messenger RNA splicing and increase production of functional proteins from disease-associated genes.

Stoke’s lead program is zorevunersen (STK-001), an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein expression in people with Dravet syndrome, a severe genetic epilepsy caused primarily by mutations in the SCN1A gene.

See Also